Sponsor: Klobuchar
Party: Amy [Sen.-D-MN] (Submitted 04/04/2025)

-- AMENDMENT TEXT --

[Page S2431]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
  SA 2111. Ms. KLOBUCHAR submitted an amendment intended to be proposed 
by her to the concurrent resolution H. Con. Res. 14
establishing the 
congressional budget for the United States Government for fiscal year 
2025 and setting forth the appropriate budgetary levels for fiscal 
years 2026 through 2034; which was ordered to lie on the table; as 
follows:
       At the appropriate place
insert the following:
     SEC. ___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO RESEARCH 
                   AND PRODUCT REVIEWS BY THE FOOD AND DRUG 
                   ADMINISTRATION FOR RARE DISEASES.
       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees

     aggregates
and other appropriate levels in this resolution

     and make adjustments to the pay-as-you-go ledger
for one or 
     more bills
joint resolutions
amendments
amendments between 
     the Houses
motions
or conference reports relating to 
     research and product reviews by the Food and Drug 
     Administration for rare diseases
which may include efforts 
     to accelerate the development and approval of treatments

     improvements in regulatory science
or support for research 
     on innovative therapies
by the amounts provided in such 
     legislation for those purposes
provided that such 
     legislation would not increase the deficit over the period of 
     the total of fiscal years 2025 through 2034.
                                 ______

04/04/2025
Senate amendment submitted
